Sam Chun Dang Pharm said on the 22nd it signed a joint development and commercialization partnership with Daiichi Sankyo Espha for the Japan sale of oral semaglutide. Daiichi Sankyo Espha is a subsidiary in charge of the Daiichi Sankyo Group's generics business.
The products for sale are generic versions of the oral GLP-1 receptor agonist Rybelsus, developed by Novo Nordisk, in 3 mg, 7 mg, and 14 mg, and oral Wegovy generics in 1.5 mg, 4 mg, 9 mg, 25 mg, and 50 mg.
The company added it plans to announce the upfront payment, milestones, and revenue-sharing ratio after signing an amended agreement once the Japan approval and price for the original oral Wegovy are determined.
※ This article has been translated by AI. Share your feedback here.